| Homepage | Forward to a Friend | Make a Donation |
 |
| eLetter #649 | March 4, 2016 |
|
|
Deadline for Scholarship Applications is Almost Here!
 The deadline for scholarship applications is right around the corner. The scholarship program is a tremendous opportunity for first time attendees to attend the National Patient Education Conference. Thanks to the generous support of many donors and chapters, conference scholarships will be available to the 2016 Conference in New Orleans, LA from July 29-31, 2016. The deadline to apply is March 17.
Click here to apply >>
|
|
Do you have an Emergency Communication Plan?
 Emergency planning can seem overwhelming but your family may not be together if a disaster strikes. It is important to know what an emergency communication plan is and why you should make one.
Click here for tips >>
|
|
Systemic Sclerosis: Nature.com Reviews Disease Primers
 Systemic sclerosis is a complex autoimmune disease characterized by a chronic and frequently progressive course and by extensive patient-to-patient variability.
Click here for more info >>
|
|
Getting Involved in Research for Chronic Pain
 Chronic pain affects more than 100 million Americans. The pain can last several years or a lifetime, but as we learn in this video, patients who take an active role in their treatment can often return to normal activities and improve their quality of life. The study in the video was funded by the non-profit Patient-Centered Outcomes Research Institute.
Click here to watch >>
|
Clinical Trial Update
|
|
Reata Pharmaceuticals Focuses Clinical Trial on Pulmonary Arterial Hypertension (PAH) Patients with Connective Tissue Disease (CTD)
Reata Pharmaceuticals announces an expansion of its clinical trial, LARIAT, that
has a focus in pulmonary arterial hypertension (PAH) patients
with connective tissue disease (CTD). Patients with systemic sclerosis as well
as other Connective Tissue Diseases are to be included in this trial.
Several scleroderma and PAH centers are participating in the
trial. Learn more by following the link below, including centers that are
currently enrolling.
http://pulmonaryhypertensionnews.com/clinical-trials/
|
|
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
 |
|
